P-selectin inhibition for treatment of cancer
AssigneeRamot at Tel-Aviv University Ltd.
InventorsRonit SATCHI-FAINARO, Eilam YEINI
Life of this patent
Estimating the term…
Abstract
A method of treating brain-metastasized cancer in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that specifically decreases an amount and/or activity of P-selectin and an immunomodulatory agent. Methods of treating additional cancers are also disclosed.
Claims20
A method of treating a cancer selected from the group consisting of brain-metastasized cancer, pancreatic cancer, lung cancer, breast cancer, primary melanoma and kidney cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that specifically decreases an amount and/or activity of P-selectin and an immunomodulatory agent, thereby treating the cancer.
A method of treating glioblastoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Crizanlizumab and an anti-PD1 antibody, thereby treating the glioblastoma or brain metastasized melanoma.
Dependencies are inferred from the claim text.